What do systematic reviews say?

Paliperidone palmitate vs placebo

The review found no eligible studies for this question.

• Paliperidone palmitate for schizophrenia 2012 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Antifibrinolytic therapy (tranexamic acid or epsilon aminocaproic acid) vs placebo/open control

• Haemostatic therapies for stroke due to acute, spontaneous intracerebral haemorrhage 2023 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 2349 participants
  High

Summary of findings: Iron vs placebo

• Iron for the treatment of restless legs syndrome 2019 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 128 participants
  Very low

Intravenous iron vs placebo

• Intravenous iron therapy for non‐anaemic, iron‐deficient adults 2019 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 344 participants
  Very low

Mepolizumab 750 mg vs placebo

• Anti‐IL‐5 therapies for chronic obstructive pulmonary disease 2020 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 18 participants
  Low

Antimicrobial lozenge vs placebo

• Pharmacological interventions for preventing dry mouth and salivary gland dysfunction following radiotherapy 2017 · Cochrane All outcomes

  Over 6 months
  Insufficient evidence of a difference for global quality of life, mouth pain RR 0.94 (95% CI 0.66 to 1.33), sore/burning mouth RR 0.95 (95% CI 0.68 to 1.35), throat pain RR 0.79 (95% CI 0.56 to 1.12) (Duncan 2005)
  1 study
  GRADE not reported

Acupuncture vs placebo

It is very uncertain whether acupuncture changes quality of life: anxiodepressive symptomatology compared with placebo (very low certainty).

• Interventions for treating hyperemesis gravidarum 2016 · Cochrane Headline outcomes only
  RR 1.01 [0.73, 1.4]
  1 study · 36 participants
  Very low

Dopamine agonist vs placebo

• Dopamine agonists for the treatment of restless legs syndrome 2011 · Cochrane Headline outcomes only
  no estimate extracted
  17 studies · 4312 participants
  Moderate

Anti‐IgE mAb (omalizumab) vs placebo (on top of topical steroids)

• Biologics for chronic rhinosinusitis 2021 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 38 participants
  Very low

Phlebotonics vs placebo?

• Phlebotonics for venous insufficiency 2020 · Cochrane Headline outcomes only
  no estimate extracted
  5 studies · 1639 participants
  Moderate

Any antiglucocorticoid vs placebo

• Antiglucocorticoid and related treatments for psychosis 2016 · Cochrane Headline outcomes only
  no estimate extracted
  0 studies · 0 participants
  GRADE not reported
• Antiglucocorticoid and related treatments for psychosis 2016 · Cochrane Headline outcomes only
  no estimate extracted
  0 studies · 0 participants
  GRADE not reported
• Antiglucocorticoid and related treatments for psychosis 2016 · Cochrane Headline outcomes only
  no estimate extracted
  0 studies · 0 participants
  GRADE not reported

Pharmacological interventions vs placebo/usual care or different forms of intervention

The review found no eligible studies for this question.

• Interventions for sexual dysfunction following stroke 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

SPRM vs placebo

• Selective progesterone receptor modulators (SPRMs) for uterine fibroids 2017 · Cochrane Headline outcomes only
  no estimate extracted
  4 studies · 171 participants
  Moderate

Recombinant human C1 esterase inhibitor vs placebo or active control

The review found no eligible studies for this question.

• Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Maintenance treatment with antipsychotic drugs vs placebo/no treatment

• Maintenance treatment with antipsychotic drugs for schizophrenia 2020 · Cochrane Headline outcomes only
  no estimate extracted
  7 studies · 1573 participants
  Low

Fexofenadine 120 mg/d vs placebo (1‐week intervention)

The review found no eligible studies for this question.

• Oral H1 antihistamines as ‘add‐on’ therapy to topical treatment for eczema 2019 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Loratadine 10 mg vs placebo (4‐week intervention)

The review found no eligible studies for this question.

• Oral H1 antihistamines as ‘add‐on’ therapy to topical treatment for eczema 2019 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Loratadine 10 mg vs placebo (2‐week intervention)

The review found no eligible studies for this question.

• Oral H1 antihistamines as ‘add‐on’ therapy to topical treatment for eczema 2019 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Cetirizine 0.5 mg/kg/d vs placebo (18‐month intervention)

The review found no eligible studies for this question.

• Oral H1 antihistamines as ‘add‐on’ therapy to topical treatment for eczema 2019 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Cetirizine 10 mg/d vs placebo (4‐week intervention)

The review found no eligible studies for this question.

• Oral H1 antihistamines as ‘add‐on’ therapy to topical treatment for eczema 2019 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found